# OnCo record nct05671822 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05671822/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05671822", "NCT05671822" ;
  schema:name "Ph1b/2 Study of the Safety and Efficacy of SHR-A1811 Combinations in Advanced HER2 Expression Gastric Cancer"@en ;
  schema:description "A phase 2 trial of Trastuzumab rezetecan, Retlirafusp alfa, Capecitabine, Adebrelimab and Oxaliplatin in gastric & gastro-oesophageal junction cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05671822/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05671822> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2023-03-14" ;
  onco:cancers <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/gastric-her2-positive/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/topoisomerase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab-rezetecan/>, <https://onco.cc/drugs/retlirafusp-alfa/>, <https://onco.cc/drugs/capecitabine/>, <https://onco.cc/drugs/adebrelimab/>, <https://onco.cc/drugs/oxaliplatin/> ;
  onco:companies <https://onco.cc/companies/hengrui/> .